https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / Cir Esp 2007 Feb;81(2):82-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / Cir Esp 2007 Feb;81(2):82-62007-02-01 00:00:002007-02-01 00:00:00[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-19 / Cancer Gene Ther. 2007 Apr;14(4):409-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-19 / Cancer Gene Ther. 2007 Apr;14(4):409-202007-01-19 00:00:002019-02-15 08:48:20Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-15 / Clin. Cancer Res. 2007 Jan;13(2 Pt 1):566-575
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-15 / Clin. Cancer Res. 2007 Jan;13(2 Pt 1):566-5752007-01-15 00:00:002019-02-15 08:59:53Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-15 / Cancer Res. 2007 Jan;67(2):429-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-15 / Cancer Res. 2007 Jan;67(2):429-322007-01-15 00:00:002019-02-15 09:22:11Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-10 / J. Virol. 2007 Mar;81(6):2817-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-10 / J. Virol. 2007 Mar;81(6):2817-302007-01-10 00:00:002019-02-15 09:00:16p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-08 / Vet. J. 2008 Jan;175(1):126-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-08 / Vet. J. 2008 Jan;175(1):126-92007-01-08 00:00:002019-02-15 09:19:35Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-03 / Vaccine 2007 Mar;25(14):2610-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-03 / Vaccine 2007 Mar;25(14):2610-92007-01-03 00:00:002007-01-03 00:00:00Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / Adv. Exp. Med. Biol. 2007;601:387-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / Adv. Exp. Med. Biol. 2007;601:387-932007-01-01 00:00:002019-02-15 09:16:56Cell technologies in immunotherapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / J. Immunother. 2007 Jan;30(1):116-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / J. Immunother. 2007 Jan;30(1):116-222007-01-01 00:00:002019-02-15 09:17:01Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / Adv. Exp. Med. Biol. 2007;601:381-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / Adv. Exp. Med. Biol. 2007;601:381-62007-01-01 00:00:002019-02-15 09:19:41Lymphocyte subpopulations in melanoma patients treated with dendritic cell vaccines
